Fiscal Update, May 17, 2004

The Fiscal Division newsletter, published weekly during session and periodically during the interim.

Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study.

IMPORTANCE: The best treatment option for primary vitreoretinal lymphoma (PVRL) without signs of central nervous system lymphoma (CNSL) involvement determined on magnetic resonance imaging or in cerebrospinal fluid is unknown. OBJECTIVE: To evaluate the outcomes of treatment regimens used for PVRL in the prevention of subsequent CNSL. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was conducted at 17 referral ophthalmologic centers in Europe. We reviewed clinical, laboratory, and imaging data on 78 patients with PVRL who did not have CNSL on presentation between January 1, 1991, and December 31, 2012, with a focus on the incidence of CNS manifestations during the follow-up period. INTERVENTIONS: The term extensive treatment was used for various combinations of systemic and intrathecal chemotherapy, whole-brain radiotherapy, and peripheral blood stem cell transplantation. Therapy to prevent CNSL included ocular radiotherapy and/or ocular chemotherapy (group A, 31 patients), extensive systemic treatment (group B, 21 patients), and a combination of ocular and extensive treatment (group C, 23 patients); 3 patients did not receive treatment. A total of 40 patients received systemic chemotherapy. MAIN OUTCOMES AND MEASURES: Development of CNSL following the diagnosis of PVRL relative to the use or nonuse of systemic chemotherapy and other treatment regimens. RESULTS: Overall, CNSL developed in 28 of 78 patients (36%) at a median follow-up of 49 months. Specifically, CNSL developed in 10 of 31 (32%) in group A, 9 of 21 (43%) in group B, and 9 of 23 (39%) in group C. The 5-year cumulative survival rate was lower in patients with CNSL (35% [95% CI, 50% to 86%]) than in patients without CNSL (68% [95% CI, 19% to 51%]; P = .003) and was similar among all treatment groups (P = .10). Adverse systemic effects occurred in 9 of 40 (23%) patients receiving systemic chemotherapy; the most common of these effects was acute renal failure. CONCLUSIONS AND RELEVANCE: In the present series of patients with isolated PVRL, the use of systemic chemotherapy was not proven to prevent CNSL and was associated with more severe adverse effects compared with local treatment.

Monsieur Badin : scène de la vie de bureau, saynète en 1 acte (Paris, Grand-Guignol, 13 avril 1897) ; et l'Extra-Lucide : saynète en 1 acte (Paris, Carillon, 17 mai 1897) / Georges Courteline

Collection : Les pièces à succès ; N° 18

Fiscal Update, August 17, 2006

The Fiscal Division newsletter, published weekly during session and periodically during the interim.

Fiscal Update, November 17, 2006

The Fiscal Division newsletter, published weekly during session and periodically during the interim.

Fiscal Update, October 17, 2008

The Fiscal Division newsletter, published weekly during session and periodically during the interim.

Fiscal Update, October 17, 2008

The Fiscal Division newsletter, published weekly during session and periodically during the interim.

Secure and Prepared Newsletter, October 2, 2007, Vol. 3, no. 17

A bi-weekly newsletter for those involved in the fields of homeland security and/or emergency management

Secure and Prepared Newsletter, December 18, 2008, Vol. 4, no. 17

A bi-weekly newsletter for those involved in the fields of homeland security and/or emergency management

Tax Credits Contingent Liabilities Brief March 17, 2009

The Tax Credits Contingent Liabilities Report was created by the Tax Research and Program Analysis Section of the Iowa Department of Revenue (IDR) for the benefit of the Revenue Estimating Conference (REC). This report is part of the Tax Credits Tracking and Analysis Program. The goal of the program is to provide a repository for information concerning the awarding, usage, and effectiveness of tax credits. This report forecasts tax credit claims assuming that all available awarded credits are issued and then, along with forecasted credits, are subsequently claimed.